Contact-
SARS-CoV-2
Anti-SARS-CoV-2 ELISA IgG / Anti-SARS-CoV-2 QuantiVac ELISA (IgG)
- Specific detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein including the immunologically relevant receptor binding domain (RBD)
- RBD represents important target antigen for virus neutralising antibodies
- Worldwide programs for vaccine development use the spike protein as antigen
- Available as ELISA for semi-quantitative (Anti-SARS-CoV-2 ELISA (IgG)) and quantitative (Anti-SARS-CoV-2 QuantiVac ELISA (IgG)) determination (same cut-off calibrator); quantitative results can NOW be given in standardised units!
- Excellent performance and good correlation with different test systems for the detection of neutralising antibodies confirmed in external studies
- Validated for serum, plasma and dried capillary blood as sample material, complete automation possible
Customer comments and testimonials about SARS-CoV-2 ELISA (IgG)
| Product | Ig class | Format | Included controls | Order no. | Status |
|---|---|---|---|---|---|
| Anti-SARS-CoV-2 ELISA | IgG | 96 x 01 | Pos. control, neg. control | EI 2606-9601 G | CE marked FDA EUA |
| Anti-SARS-CoV-2 QuantiVac ELISA (IgG) | IgG | 96 x 01 | EI 2606-9601-10 G | CE marked |
Anti-SARS-CoV-2 Omicron ELISA (IgG)
- Quantitative determinations of IgG antibodies against SARS-CoV-2 based on the recombinant S1 domain of the spike protein of the SARS-CoV-2 Omicron variant* as antigen
- Extension of the SARS-CoV-2 ELISA portfolio due to the worldwide spread of the Omicron variant
- Validated for serum and plasma as sample material, full automation possible
*The test also detects antibodies against other SARS-CoV-2 variants.
| Product | Ig class | Format | Included controls | Order no. | Status |
|---|---|---|---|---|---|
| Anti-SARS-CoV-2 Omicron ELISA (IgG) | IgG | 96 x 01 | Pos. control, neg. control | EI 2606-9601-30 G | CE marked |
Anti-SARS-CoV-2 NCP ELISA (IgG)
- Sensitive detection of IgG or IgM antibodies against SARS-CoV-2 using the nucleocapsid protein
- Antigen with the strongest immune dominance in the coronavirus family
- Optimised specificity of the ELISA due to the use of a modified nucleocapsid protein (NCP) that only contains diagnostically relevant epitopes
- Validated for serum, plasma and dried capillary blood (DBS only in combination with the IgG ELISA) as sample material, complete automation possible
| Product | Ig class | Format | Included controls | Order no. | Status |
|---|---|---|---|---|---|
| ELISA | IgG | 96 x 01 | Pos. control, neg. control | EI 2606-9601-2 G | CE marked |
Anti-SARS-CoV-2 ELISA IgA
- Sensitive ELISA for the determination of IgA against SARS-CoV-2 with optimised specificity due to use of the Sample Buffer PLUS
- Use of the S1 domain of the spike protein as the antigen
- For monitoring of the immune response after positive direct pathogen detection
| Product | Ig class | Format | Included controls | Order no. | Status |
|---|---|---|---|---|---|
| ELISA | IgA | 96 x 01 | Pos. control, neg. control | EI 2606-9601 A | CE marked |
In a nutshell: Product features of the EUROIMMUN ELISAs for COVID-19 diagnostics
| Product feature | Anti-SARS-CoV-2 ELISA (IgG) | Anti-SARS-CoV-2 QuantiVac ELISA (IgG) | Anti-SARS-CoV-2 ELISA (IgA) | Anti-SARS-CoV-2 NCP ELISA (IgG) | Anti-SARS-CoV-2 Omicron ELISA (IgG) |
|---|---|---|---|---|---|
| Antigen | S1 domaine of the spike protein | Modified nucleocapsid protein (NCP) | S1 domain of the spike protein of the SARS-CoV-2 Omicron variant** | ||
| Sample material | Serum, plasma, DBS | Serum, plasma, DBS | Serum, plasma | Serum, plasma, DBS | Serum, plasma |
| Sensitivity | 94.4 % (>10 days***) | 90.3 % (>10 days***) | 96.9 % (11 - 60 days***) | 94.6 % (>10 days***) | 86.7 % (≥21 days***) |
| Specificity | 99.6 % | 99.8 % | 98.3 % | 99.8 % | 99.8 % |
| Complete automation of DBS analyses | Possible | Possible | - | Possible | - |
| ELISA automation | EUROLabWorkstation ELISA (ELW ELISA), EUROIMMUN Analyzer I, EUROIMMUN Analyzer I-2P, Sprinter XL | ||||
| Stability of test kits | 12 months | ||||
**The test also detects antibodies against other SARS-CoV-2 variants
***after symptom onset or positive direct detection
Options for automated processing of the EUROIMMUN ELISA
1. EUROIMMUN Automation Solutions:
EUROLabWorkstation ELISA, Analyzer I, Analyzer I-2P and Sprinter XL
For further information on our automation options, please contact our experts of product management for instruments and software.
2. Processing on all common open ELISA platforms
Products
- RT-PCR
- Microarray
- Antibody detection (ELISA)
- Antibody detection (ChLIA)
- Antibody detection (Immunoblot)
- Surrogate virus neutralisation test
- Quan-T-Cell (IGRA)
- Blood collection card - Dried Blood Spots
Products may not be licensed in accordance with the laws and regulations in all countries.
Information -
SARS-CoV-2 variants
According to the well-founded assessment of our scientists, it is not to be expected that the SARS-CoV-2 variants Alpha, Beta, Gamma and Delta have any effect on the performance of our test systems. The experimental data is not yet available to make a statement on the possible effects of the Omicron variant.
Find out more here.
Contact
Please contact your
local distributor for further information.
